Abstract 76P
Background
Circulating tumor DNA (ctDNA) represents a promising prognostic biomarker for predicting relapse and overall survival in patients with metastatic pancreatic cancer (PC). To test the clinical applicable prognostic value of ctDNA dynamics during treatment, we aimed to detect response to treatment ahead of radiological restaging.
Methods
ctDNA detection using liquid biopsy (ddPCR utilizing KRAS G12/13 (and, if negative, Q61) commercial test kits) was prospectively performed on 70 patients with stage IV PC (i) prior to initiation of systemic chemotherapy and (ii) serially every two weeks until restaging.
Results
Detection rate at baseline was 64.3% (45/70). Reduction of ctDNA levels below 57.9% of its baseline value at week 2 after treatment initiation was significantly predictive for response to treatment (AUC=0.918, sensitivity 91.67%, specificity 100%) and was associated with prolonged overall survival (OS) (5.7 vs. 11.4 months, p=0.006) and progression free survival (PFS) (2.5 vs. 7.7 months, p<0.000) regardless of treatment line. Pretherapeutic ctDNA detection was independently associated with worse OS in patients receiving first line regimen (7 vs. 11.3 months, p=0.046) and regardless of treatment line (11.4 vs. 15.9 months, p=0.045) and associated with worse PFS (3.4 vs. 10.8 months, p=0.018).
Conclusions
The dynamic change of ctDNA during systemic treatment allows the prediction of treatment response and is associated with OS and PFS. Progressive disease was correctly predicted in 100% of patients with preemptive detectable ctDNA after 2 weeks (ctDNA) compared to 12 weeks with current gold standard (CT), enabling change of treatment >80% earlier hereafter.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Rumpold.
Funding
Vinzenzgruppe Austria and Krebshilfe Oberösterreich.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract